Fig. 7: The effect of inhaled TP-10@CaP-CTP on cardiac function. | Nature Communications

Fig. 7: The effect of inhaled TP-10@CaP-CTP on cardiac function.

From: Inhalable cardiac targeting peptide modified nanomedicine prevents pressure overload heart failure in male mice

Fig. 7

a Schematic of the mouse cardiac function evaluation and CM shortening/relengthening assays. After six weeks of inhalation treatment with PBS, TP-10 (0.75 mg/kg/2 days), CaP-CTP (2.5 mg/kg/2 days), TP-10@CaP (2.5 mg/kg/2 days) or TP-10@CaP-CTP (2.5 mg/kg/2 days), the mice were subjected to ultrasound cardiography, and CMs were isolated from the left ventricle for shortening/relengthening assays. b Representative echocardiography images from each study group after six weeks of treatment. c–g Percent ejection fraction (EF%), percent fraction shortening (FS%), left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), and the E/A ratio. n = 8 mice in each group. h–m Primary CMs were isolated from each study group at the 8-week time point prior to mechanical assessment. Resting cell length, peak shortening (PS), maximal velocity of shortening (+dL/dt), maximal velocity of relengthening (−dL/dt), time to peak shortening (TPS), and time to 90% relengthening (TR90) were measured. n = 58 CMs from 3 mice in each group. The results are presented as the mean ± SD. For c–m, statistical analysis was performed using one-way ANOVA with the Bonferroni multiple comparison correction. Source data are provided as a Source Data file.

Back to article page